EXEL - Trade Savi - 360-degree view on crypto market

EXEL GILD JNJ MRK NOVN PFE

Unsupported price hikes added $815 million to US drug spending in 2023

A report reveals five drugs accounted for $815 million in U.S. spending increases in 2023 without clinical evidence, highlighting ongoing pricing issues in the pharmaceutical industry.

investing.com • 12/12/2024 - 13:03 PM

AMGN EXEL GILD IDYA JAZZ REGN VRTX

RBC's top 10 questions and answers on biotech stocks

RBC Capital Markets reveals top 10 investor questions on biotech sector, focusing on FDA impact, major companies' strategies, upcoming trial data, and market sentiment.

investing.com • 13/11/2024 - 22:39 PM

EXEL

Earnings call: Exelixis reports solid growth, raises 2024 revenue guidance

Exelixis reported strong Q3 results, increasing revenues by 9%, raising year guidance, and focusing on oncology portfolio expansion, including collaborations and potential new product launches.

investing.com • 31/10/2024 - 11:50 AM

EXEL

Exelixis EVP Jeffrey Hessekiel sells shares worth over $659k

Jeffrey Hessekiel sold 25,000 shares of Exelixis, netting over $659,000. Company shows strong Q2 2024 performance, while UBS expresses caution regarding future growth.

investing.com • 25/09/2024 - 23:35 PM

Greed and Fear Index

Note: The data is for reference only.

Extreme Greed

Unsupported price hikes added $815 million to US drug spending in 2023

RBC's top 10 questions and answers on biotech stocks

Earnings call: Exelixis reports solid growth, raises 2024 revenue guidance

Exelixis EVP Jeffrey Hessekiel sells shares worth over $659k

Greed and Fear Index

Currency